New stable synthetic bacteriochlorins for photodynamic therapy of melanoma

Pawel Mroz, Ying Ying Huang, Sahar Janjua, Timur Zhiyentayev, Christian Ruzié, K. Eszter Borbas, Dazhong Fan, Michael Krayer, Thiagarajan Balasubramanian, Eun Kyung Yang, Hooi Ling Kee, Dewey Holten, Jonathan S. Lindsey, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.

Original languageEnglish (US)
Title of host publication12th World Congress of the International Photodynamic Association - Photodynamic Therapy
Subtitle of host publicationBack to the Future
DOIs
StatePublished - Dec 1 2009
Event12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future - Seattle, WA, United States
Duration: Jun 11 2009Jun 15 2009

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume7380
ISSN (Print)1605-7422

Other

Other12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future
CountryUnited States
CitySeattle, WA
Period6/11/096/15/09

Fingerprint

Photodynamic therapy
Photosensitizing Agents
Photosensitizers
Photochemotherapy
Melanoma
therapy
Melanin
melanin
Melanins
Melanosomes
cancer
Cells
Light
Cell death
death
Basal Cell Carcinoma
Light absorption
Electron microscopy
Dosimetry
Skin Neoplasms

Keywords

  • bacteriochlorins
  • melanoma
  • melanosomes
  • multidrug resistance
  • photodynamic therapy

Cite this

Mroz, P., Huang, Y. Y., Janjua, S., Zhiyentayev, T., Ruzié, C., Borbas, K. E., ... Hamblin, M. R. (2009). New stable synthetic bacteriochlorins for photodynamic therapy of melanoma. In 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future [73802S] (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 7380). https://doi.org/10.1117/12.823060

New stable synthetic bacteriochlorins for photodynamic therapy of melanoma. / Mroz, Pawel; Huang, Ying Ying; Janjua, Sahar; Zhiyentayev, Timur; Ruzié, Christian; Borbas, K. Eszter; Fan, Dazhong; Krayer, Michael; Balasubramanian, Thiagarajan; Yang, Eun Kyung; Kee, Hooi Ling; Holten, Dewey; Lindsey, Jonathan S.; Hamblin, Michael R.

12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. 2009. 73802S (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 7380).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mroz, P, Huang, YY, Janjua, S, Zhiyentayev, T, Ruzié, C, Borbas, KE, Fan, D, Krayer, M, Balasubramanian, T, Yang, EK, Kee, HL, Holten, D, Lindsey, JS & Hamblin, MR 2009, New stable synthetic bacteriochlorins for photodynamic therapy of melanoma. in 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future., 73802S, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 7380, 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future, Seattle, WA, United States, 6/11/09. https://doi.org/10.1117/12.823060
Mroz P, Huang YY, Janjua S, Zhiyentayev T, Ruzié C, Borbas KE et al. New stable synthetic bacteriochlorins for photodynamic therapy of melanoma. In 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. 2009. 73802S. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE). https://doi.org/10.1117/12.823060
Mroz, Pawel ; Huang, Ying Ying ; Janjua, Sahar ; Zhiyentayev, Timur ; Ruzié, Christian ; Borbas, K. Eszter ; Fan, Dazhong ; Krayer, Michael ; Balasubramanian, Thiagarajan ; Yang, Eun Kyung ; Kee, Hooi Ling ; Holten, Dewey ; Lindsey, Jonathan S. ; Hamblin, Michael R. / New stable synthetic bacteriochlorins for photodynamic therapy of melanoma. 12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future. 2009. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE).
@inproceedings{ab17b83b5e1f43f79a45e2d53f0a6666,
title = "New stable synthetic bacteriochlorins for photodynamic therapy of melanoma",
abstract = "Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.",
keywords = "bacteriochlorins, melanoma, melanosomes, multidrug resistance, photodynamic therapy",
author = "Pawel Mroz and Huang, {Ying Ying} and Sahar Janjua and Timur Zhiyentayev and Christian Ruzi{\'e} and Borbas, {K. Eszter} and Dazhong Fan and Michael Krayer and Thiagarajan Balasubramanian and Yang, {Eun Kyung} and Kee, {Hooi Ling} and Dewey Holten and Lindsey, {Jonathan S.} and Hamblin, {Michael R.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1117/12.823060",
language = "English (US)",
isbn = "9780819476609",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
booktitle = "12th World Congress of the International Photodynamic Association - Photodynamic Therapy",

}

TY - GEN

T1 - New stable synthetic bacteriochlorins for photodynamic therapy of melanoma

AU - Mroz, Pawel

AU - Huang, Ying Ying

AU - Janjua, Sahar

AU - Zhiyentayev, Timur

AU - Ruzié, Christian

AU - Borbas, K. Eszter

AU - Fan, Dazhong

AU - Krayer, Michael

AU - Balasubramanian, Thiagarajan

AU - Yang, Eun Kyung

AU - Kee, Hooi Ling

AU - Holten, Dewey

AU - Lindsey, Jonathan S.

AU - Hamblin, Michael R.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.

AB - Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.

KW - bacteriochlorins

KW - melanoma

KW - melanosomes

KW - multidrug resistance

KW - photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=77956633870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956633870&partnerID=8YFLogxK

U2 - 10.1117/12.823060

DO - 10.1117/12.823060

M3 - Conference contribution

SN - 9780819476609

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - 12th World Congress of the International Photodynamic Association - Photodynamic Therapy

ER -